<DOC>
	<DOCNO>NCT02673463</DOCNO>
	<brief_summary>This study aim ass whether treatment drug call spironolactone , aldosterone inhibitor , improve ability cope exertion , quality life ability heart relax well symptomatic patient atrial fibrillation preserve pumping capacity .</brief_summary>
	<brief_title>Spironolactone Atrial Fibrillation</brief_title>
	<detailed_description>IMPRESS-AF study double-blinded randomise placebo-controlled trial 2-year treatment aldosterone antagonist , spironolactone ( 25mg daily ) v placebo 250 patient symptomatic chronic atrial fibrillation preserve leave ventricular contractility ( added current optimise care ) . The trial establish impact spironolactone primary outcome exercise tolerance ( peak oxygen consumption cardiopulmonary exercise test ) secondary outcome : ( ) health-related quality life ( assessed use validated Minnesota Living Heart Failure EuroQol EQ-5D questionnaires self-completed patient ) , ( ii ) leave ventricular diastolic function ( E/e ' ratio echocardiography ) - assess baseline 2 year ; ( iii ) rate all-cause hospitalisation 2-year follow-up .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Permanent AF Left ventricular ejection fraction &gt; = 55 % establish echocardiography Able perform cardiopulmonary exercise test use cycle ergometer complete quality life questionnaire English native language . Severe systemic illness ( life expectancy &lt; 2 year ) Severe chronic obstructive pulmonary disease ( e.g. , require home oxygen chronic oral steroid therapy ) Severe mitral/aortal valve stenosis/regurgitation Significant renal dysfunction ( serum creatinine 220 Âµmol/L ) , anuria , active renal insufficiency , rapidly progress severe impairment renal function , confirm suspect renal insufficiency diabetic patients/ diabetic nephropathy Increase potassium level &gt; 5mmol/L Recent coronary artery bypass graft surgery ( within 3 month ) Use aldosterone antagonist within 14 day randomisation Use potassium spar diuretic within 14 day randomisation Systolic blood pressure &gt; 160 mm Hg Addison 's disease Hypersensitivity spironolactone ingredient product Any participant characteristic may interfere adherence trial protocol</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>